Archives for News - Page 10
90% of the cases analysed are carriers of at least one genetic mutation
Custom Synthesis, Conceiving and bearing a child is a blessing in a couple’s life. While they are lost in rejoicing the good news, they often...
Adding blueberries to the diet may be an overall positive diet
Custom Synthesis, New research published in the European Journal of Nutrition found that daily consumption of the equivalent of one cup of fresh blueberries, given...
Xbrane Biopharma to deliver its cancer drug to Middle East
Custom Synthesis, Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to...
Cannabics Pharmaceuticals gets final report of its research on antitumor properties of cannabinoids in Israel
Custom Synthesis, Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity...
Novartis in-licenses dry eye therapeutic ECF843 worldwide
Custom Synthesis, Novartis said Thursday it has exercised an option to in-license ECF843 for ophthalmic indications worldwide excepot of Europe, without revealing financial and other...
Tiziana testing drug for fifth most common cancer
Custom Synthesis, Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle...
Sobi’s hereditary tyrosinemia drug approved in Saudi Arabia
Custom Synthesis, The Saudi Food and Drug Administration (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Orfadin (nitisinone) capsules in all strengths (2 mg, 5 mg,...
Sobi to sell another rare disease drug in Saudi Arabia
Custom Synthesis, The Saudi Food & Drug Authority (SFDA) has approved Swedish Orphan Biovitrum’s (Sobi) Elocta (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein...
Destiny Pharma names new non-executive director
Custom Synthesis, Destiny Pharm has consolidate its board with appointing Nick Rodgers as an independent Non-Executive Director with immediate effect. Rodgers has considerable Board experience...
Santhera’s Raxone Early Acces to Medicines Scheme renewed in UK
Custom Synthesis, Santhera Pharmaceuticals’s Raxone has been renewed in UK, as the nation’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed the Early Access...